Galmed Pharmaceuticals (GLMD) EBITDA Margin (2016 - 2018)
Galmed Pharmaceuticals (GLMD) recorded quarterly EBITDA Margin of 62.67% in Q3 2018, down 93.68% quarter-over-quarter from 991.85% in Q2 2018, and down 95895.0% on a YoY basis from N/an in Q3 2017.
Galmed Pharmaceuticals (GLMD) EBITDA Margin (2016 - 2018) Analysis & Trends
Galmed Pharmaceuticals' EBITDA Margin history runs 3 years deep, the most recent figure standing at 62.67% for Q3 2018.
- In Q3 2018, EBITDA Margin fell 95895.0% year-over-year to 62.67%; the TTM figure through Jun 2019 stood at 692.37% (down 38099.0% YoY), while the FY2018 annual figure was 57.61%, up 119714.0% from the prior year.
- EBITDA Margin was 62.67% for Q3 2018 at Galmed Pharmaceuticals, down from 991.85% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2001.55% in Q3 2016 to a low of 62.67% in Q3 2018.
- Historically, EBITDA Margin has averaged 1145.12% across 3 years, with a median of 1021.61% in 2017.
- The sharpest annual moves came in 2017 and 2018: EBITDA Margin sank 97994 bps in 2017, then plunged 185 bps in 2018.
- A 3-year view of EBITDA Margin shows it stood at 1787.96% in 2016, then fell by 26 bps to 1329.93% in 2017, then plunged by 95 bps to 62.67% in 2018.
- The last three EBITDA Margin figures came in at 62.67% (Q3 2018), 991.85% (Q2 2018), and 945.9% (Q1 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 62.67% |
| Jun 30, 2018 | 991.85% |
| Mar 31, 2018 | 945.90% |
| Dec 31, 2017 | 1,329.93% |
| Sep 30, 2017 | 1,021.61% |
| Jun 30, 2017 | 993.70% |
| Mar 31, 2017 | 1,170.90% |
| Dec 31, 2016 | 1,787.96% |
| Sep 30, 2016 | 2,001.55% |